Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
Phase 1 Recruiting
50 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Phase 1 Recruiting
300 enrolled
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Phase 1 Recruiting
36 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 Recruiting
399 enrolled
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Phase 1 Recruiting
86 enrolled
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
604 enrolled
A Study of XMT-1660 in Participants With Solid Tumors
Phase 1 Recruiting
319 enrolled
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Phase 1 Recruiting
60 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Phase 1 Recruiting
45 enrolled
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 Recruiting
383 enrolled
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 Recruiting
100 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.
Phase 1 Recruiting
40 enrolled
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Phase 1 Recruiting
36 enrolled
KOMODO-1
Phase 1 Recruiting
96 enrolled
HLD-0117
Phase 1 Recruiting
33 enrolled
CBD for Breast Cancer Primary Tumors
Phase 1 Recruiting
84 enrolled
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 Recruiting
162 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
386 enrolled
PAveMenT
Phase 1 Recruiting
45 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Phase 1 Recruiting
136 enrolled
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Phase 1 Recruiting
64 enrolled
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
Phase 1 Recruiting
28 enrolled
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Phase 1 Recruiting
138 enrolled
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 Recruiting
280 enrolled
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Phase 1 Recruiting
40 enrolled
CHANCES
Phase 1 Recruiting
27 enrolled
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Phase 1 Recruiting
48 enrolled
OMNIRAY
Phase 1 Recruiting
421 enrolled
FiREBOLT
Phase 1 Recruiting
241 enrolled
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Phase 1 Recruiting
180 enrolled
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
205 enrolled
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Phase 1 Recruiting
110 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
Phase 1 Recruiting
61 enrolled
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Phase 1 Recruiting
70 enrolled
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Phase 1 Recruiting
60 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
GUARDIAN-101
Phase 1 Recruiting
90 enrolled
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Phase 1 Recruiting
28 enrolled
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
Phase 1 Recruiting
60 enrolled
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
80 enrolled
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Phase 1 Recruiting
18 enrolled
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
216 enrolled